MINIREVIEWS

6031 Diabetes among Muslims during Ramadan: A narrative review
Ochani RK, Shaikh A, Batra S, Pikale G, Surani S

ORIGINAL ARTICLE

Retrospective Cohort Study

6040 Clinical evaluation of ventilation mode on acute exacerbation of chronic obstructive pulmonary disease with respiratory failure
Wang JJ, Zhou Z, Zhang LY

Retrospective Study

6051 Predictive value of preoperative albumin-bilirubin score and other risk factors for short-term outcomes after open pancreatoduodenectomy
Zavrtanik H, Cosola D, Badovinac D, Hadžialjević B, Horvat G, Plevel D, Bogoni S, Tarchi P, de Manzini N, Tomažič A

6066 Lyophilized recombinant human brain natriuretic peptide for chronic heart failure: Effects on cardiac function and inflammation
Li F, Li H, Luo R, Pei JB, Yu XY

6073 Continuous renal replacement therapy with oXiris® in patients with hematologically malignant septic shock: A retrospective study

6083 Serum basic fibroblast growth factor and interleukin-1β predict the effect of first-line chemotherapy in patients with advanced gastric cancer
Zheng L, Gan LH, Yao L, Li B, Huang YQ, Zhang FB, Kuang MQ, Fang N

6091 Multinucleated giant cells of bladder mucosa are modified telocytes: Diagnostic and immunohistochemistry algorithm and relation to PD-L1 expression score
Gulinac M, Velikova T, Dikov D

Clinical Trials Study

6105 Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients
Hegazy SK, Tharwat S, Hassan AH

META-ANALYSIS

6122 Risk factors for stroke recurrence in young patients with first-ever ischemic stroke: A meta-analysis
Xia Y, Liu H, Zhu R
## CONTENTS

**SCIENTOMETRICS**

- **6132** Unveiling the hidden world of gut health: Exploring cutting-edge research through visualizing randomized controlled trials on the gut microbiota
  

**CASE REPORT**

- **6147** Rivaroxaban for the treatment of heparin-induced thrombocytopenia with thrombosis in a patient undergoing artificial hip arthroplasty: A case report
  
  Lv FF, Li MY, Qu W, Jiang ZS

- **6154** Mepolizumab induced palmoplantar psoriasis: A case report
  
  Artosi F, Diluvio L, Vultaggio M, Campione E, Bianchi L

- **6159** Early diagnosis of renal pelvis villous adenoma: A case report
  
  Li LL, Song PX, Xing DF, Liu K

- **6165** Identification of the dominant loop of a dual-loop macro-reentry left atrial flutter without prior intervention using high-density mapping technology: A case report
  
  Yu SD, Chu YP

- **6170** Surgery for fibrous dysplasia associated with aneurysmal-bone-cyst-like changes in right proximal femur: A case report
  
  Xie LL, Yuan X, Zhu HX, Pu D

- **6176** Efficacy of abatacept treatment in a patient with enteropathy carrying a variant of unsignificance in CTLA4 gene: A case report
  
  Musabak U, Erdoğan T, Ceylaner S, Özbek E, Suna N, Özdemir BH

- **6183** Postpartum hemophagocytic lymphohistiocytosis: A case report
  
  An JH, Ahn JH

- **6189** Non-arteritic anterior ischemic optic neuropathy combined with branch retinal vein obstruction: A case report
  
  Gong HX, Xie SY

- **6194** Large colonic lipoma with a laterally spreading tumor treated by endoscopic submucosal dissection: A case report
  
  Bae JY, Kim HK, Kim YJ, Kim SW, Lee Y, Ryu CB, Lee MS

- **6200** T/myeloid mixed-phenotype acute leukemia treated with venetoclax and decitabine: A case report
  
  Park S, Jeong EJ, Kang JH, Lee GW, Go SI, Lee DH, Koh EH

- **6206** Severe inflammatory disorder in trisomy 8 without myelodysplastic syndrome and response to methylprednisolone: A case report
  
  Pan FY, Fan HZ, Zhuang SH, Pan LF, Ye XY, Tong HJ
## Contents

**Thrice Monthly Volume 11 Number 26 September 16, 2023**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>6213</td>
<td>Aggressive variant prostate cancer: A case report and literature review</td>
<td>Weng XT, Lin WL, Pan QM, Chen TF, Li SY, Gu CM</td>
</tr>
<tr>
<td>6231</td>
<td>Left epigastric isolated tumor fed by the inferior phrenic artery diagnosed as ectopic hepatocellular carcinoma: A case report</td>
<td>Liu HB, Zhao LH, Zhang YJ, Li ZF, Li L, Huang QP</td>
</tr>
<tr>
<td>6240</td>
<td>Squamous cell carcinoma associated with endometriosis in the uterus and ovaries: A case report</td>
<td>Zhang JM, Zheng CW, Li XW, Fang ZY, Yu MX, Shen HY, Ji X</td>
</tr>
<tr>
<td>6246</td>
<td>Intestinal obstruction due to giant liver cyst: A case report</td>
<td>Liu HB, Zhao LH, Zhang YJ, Li ZF, Li L, Huang QP</td>
</tr>
<tr>
<td>6252</td>
<td>Difficulties in diagnosing angiomatoid fibrous histiocytoma of the head and neck region: A case report</td>
<td>Liu HB, Zhao LH, Zhang YJ, Li ZF, Li L, Huang QP</td>
</tr>
<tr>
<td>6274</td>
<td>Variant of Guillain-Barré syndrome with anti-sulfatide antibody positivity and spinal cord involvement: A case report</td>
<td>Liu H, Lv HG, Zhang R</td>
</tr>
<tr>
<td>6289</td>
<td>Collision tumor of primary malignant lymphoma and adenocarcinoma in the colon diagnosed by molecular pathology: A case report and literature review</td>
<td>Jiang M, Yuan XP</td>
</tr>
<tr>
<td>6298</td>
<td>Successful resolution of gastric perforation caused by a severe complication of pancreatic walled-off necrosis: A case report</td>
<td>Noh BG, Yoon M, Park YM, Seo HI, Kim S, Hong SB, Park JK, Lee MW</td>
</tr>
<tr>
<td>6304</td>
<td>Bilateral dislocation of the long head of biceps tendon with intact rotator cuff tendon: A case report</td>
<td>Sohn HJ, Cho CH, Kim DH</td>
</tr>
</tbody>
</table>
6311  Delayed diagnosis of abdominal Henoch-Schönlein purpura in children: A case report

Guo H, Wang ZL, Tao Z
About Cover
Editorial Board Member of World Journal of Clinical Cases, Vikram K Mahajan, MD, Professor, Dermatology, Venereology and Leprosy, Dr. Radhakrishnan Government Medical College, Kangra 177001, Himachal Pradesh, India. vkm1@rediffmail.com

Aims and Scope
The primary aim of World Journal of Clinical Cases (WJCC, World J Clin Cases) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

Indexing/Abstracting
The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstars Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJCC as 1.1; IF without journal self cites: 1.1; 5-year IF: 1.3; Journal Citation Indicator: 0.26; Ranking: 133 among 167 journals in medicine, general and internal; and Quartile category: Q4.

Responsible Editors for This Issue
Production Editor: Hua-Ge Yu; Production Department Director: Xu Guo; Editorial Office Director: Jin-Lei Wang.

Name of Journal
World Journal of Clinical Cases

ISSN
ISSN 2307-8960 (online)

Launch Date
April 16, 2013

Frequency
Thrice Monthly

Editors-In-Chief
Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

Editorial Board Members
https://www.wjgnet.com/2307-8960/editorialboard.htm

Publication Date
September 16, 2023

Copyright
© 2023 Baishideng Publishing Group Inc

Instructions to Authors
https://www.wjgnet.com/bpg/gerinfo/204

Guidelines for Ethics Documents
https://www.wjgnet.com/bpg/gerinfo/287

Guidelines for Non-Native Speakers of English
https://www.wjgnet.com/bpg/gerinfo/240

Publication Ethics
https://www.wjgnet.com/bpg/gerinfo/288

Publication Misconduct
https://www.wjgnet.com/bpg/gerinfo/208

Article Processing Charge
https://www.wjgnet.com/bpg/gerinfo/242

Steps for Submitting Manuscripts
https://www.wjgnet.com/bpg/gerinfo/239

Online Submission
https://www.f6publishing.com
Efficacy of abatacept treatment in a patient with enteropathy carrying a variant of unsignificance in CTLA4 gene: A case report

Ugur Musabak, Tuba Erdoğan, Serdar Ceylaner, Emre Özbek, Nuretdin Suna, Binnaz Handan Özdemir

Abstract

BACKGROUND

Cytotoxic T Lymphocyte Antigen-4 (CTLA4) deficiency is a genetic defect that causes a common variable immunodeficiency (CVID) clinical phenotype. Several studies have reported an association between CTLA mutations or variants and various autoimmune diseases. Targeted therapy models, which have become increasingly popular in recent years, have been successful in treating CTLA4 deficiency. In this article, we discuss the clinical outcomes of abatacept treatment in a patient with CTLA4 and lipopolysaccharide-responsive beige-like anchor (LRBA) variants that was previously diagnosed with CVID.

CASE SUMMARY

A 25-year-old female patient, who was visibly cachectic, visited our clinic over the course of five years, complaining of diarrhea. The patient was diagnosed with ulcerative colitis in the centers she had visited previously, and various treatments were administered; however, clinical improvement could not be achieved. Severe hypokalemia was detected during an examination. Her serum immunoglobulin levels, CD19+ B-cell percentage, and CD4/CD8 ratio were low. An endoscopic
examination revealed erosive gastritis, nodular duodenitis, and pancolitis. Histopathological findings supported the presence of immune mediated enteropathy. When the patient was examined carefully, she was diagnosed with CVID, and intravenous immunoglobulin treatment was initiated. Peroral and rectal therapeutic drugs including steroid therapy episodes were administered to treat the immune mediated enteropathy. Strict follow-ups and treatment were performed due to the hypokalemia. After conducting genetic analyses, the CTLA4 and LRBA variants were identified and abatacept treatment was initiated. With targeted therapy, the patient’s clinical and laboratory findings rapidly regressed, and there was an increase in weight.

CONCLUSION
The heterozygous CTLA4 variant identified in the patient has been previously shown to be associated with various autoimmune diseases. The successful clinical outcome of abatacept treatment in this patient supports the idea that this variant plays a role in the immunopathogenesis of the disease. In the presence of severe disease, abatacept therapy should be considered until further testing can be conducted.

Key Words: Common variable immunodeficiency; Abatacept; CTLA4 antigen; Case report

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: In this article, a 25-year-old female patient who applied to our outpatient clinic with the complaints of severe diarrhea and weight loss is presented. As a result of the clinical examination, laboratory tests and histopathological examinations, the patient was diagnosed with common variable immunodeficiency with severe enteropathy. Variants of uncertain significance were detected in 1 cytotoxic T lymphocyte antigen-4 (CTLA4) gene region and 2 lipopolysaccharide-responsive beige-like anchor gene regions in the patient who underwent Whole Exome Sequencing test. Although these polymorphisms have been listed as non-pathogenic in the variant database, their association with some autoimmune diseases had been shown in the literature before. CTLA4-Ig fusion protein, which had been shown to be effective in these autoimmune diseases, was administered to our patient without delay and a dramatic improvement was achieved in clinical findings.

INTRODUCTION
Cytotoxic T lymphocyte antigen-4 (CTLA4) deficiency is an autosomal dominant primary immunodeficiency disease, in which both parental copies of the related gene must be healthy for adequate expression[1]. This disorder is also referred to as CTLA4 haploinsufficiency. This molecule, which has an inhibitory function, is constitutively expressed in activated conventional and regulatory T cells (Tregs). The main function of CTLA4 is to compete with the CD28 molecule for binding to CD80/86, which is expressed on antigen-presenting cell (APC) surfaces. T cell activation induced by the CD28 molecule is controlled by CTLA-4; therefore, unpreventable T cell activation and autoimmunity may occur during CTLA4 deficiency. Hence, this molecule is an essential regulator of T cell immunity.

CTLA4 deficiency affects many systems and causes dysfunction in some organs due to T lymphocyte accumulation[2]. The main organs affected by lymphocytic infiltration are the lungs, liver, intestine, bone marrow, lymph nodes, and spleen. Consequently, signs and symptoms appear depending on the organ affected by the disease. These patients are prone to autoimmune diseases and are at high risk of developing lymphoma.

Lipopolysaccharide-responsive beige-like anchor (LRBA) deficiency is inherited from both parents in an autosomal recessive pattern[1]. This molecule has a protective role against the degradation of CTLA-4 in lysosomes. In addition, LRBA recycles CTLA4-containing vesicles in the plasma membrane. Thus, LRBA deficiency disrupts the trafficking of CTLA-4-containing vesicles through cells and their expression on the cell surface. Consequently, the disease phenotype of LRBA deficiency is similar to that of CTLA4 deficiency. The risks of autoimmunity, lymphoproliferation, and malignancy increase in the absence of molecules involved in the same pathway.

Abatacept comprises the extracellular domain of CTLA-4 and the Fc portion of IgG1 (a CTLA4-Ig fusion protein)[3]. Abatacept terminates T cell activation by binding to the co-stimulatory molecules, CD80 and CD86, on APCs. Thus, this agent blocks activation signals by interfering with the interaction between CD28 and these co-stimulatory molecules. Recently, considerable success has been achieved with abatacept, which is a targeted therapeutic agent, for the treatment of CTLA4 and LRBA deficiencies[4].

Common variable immunodeficiency (CVID) is a multifactorial disease characterized by antibody deficiency, recurrent infections, autoimmunity, and malignancy[5]. High-resolution genetic analyses, especially in cases of CVID complicated by inflammatory bowel disease, have revealed that the underlying genetic defects are often CTLA4 haploinsufficiency and LRBA deficiency[5,6]. Most patients with these genetic defects experience diarrhea and weight loss. Here, we report a
patient with severe immune-mediated enteropathy carrying a variant of uncertain significance in the CTLA4 gene, whose clinical findings improved almost completely after abatacept therapy.

CASE PRESENTATION

Chief complaints
Five years prior to this report, a 25-year-old female patient visited our outpatient clinic complaining of watery stools at least 15 times a day. Accompanying complaints included abdominal pain, bloating, nausea, and appetite loss. The patient stated that the consistency of her stool increased from time to time; however, in most cases, it smelled poorly and had an oily appearance, and was bloody and contained mucus.

History of present illness
The patient stated that she had been experiencing these symptoms for five years and had been diagnosed with infectious diarrhea or ulcerative colitis at various centers. The patient had received treatment; however, did not benefit from the treatment and the symptoms remained, resulting in dramatic weight loss.

History of past illness
The patient’s past history was unremarkable.

Personal and family history
There was no family history of these symptoms. There was also no consanguinity between parents.

Physical examination
Upon physical examination, the patient appeared cachectic. She was 168 cm tall and weighed 46 kg [Body mass index (BMI): 16.3]. She presented with pale skin and conjunctiva, dry skin and tongue, and a post-nasal purulent discharge was also observed. Auscultation revealed a 2/6 systolic murmur without radiation in the mitral focus and wheezing in the middle and lower zones of both lungs. Dullness was detected in the Traube area using percussion. Neither rebound nor defense was detected in the abdominal quadrants. Hypoactive bowel sounds were observed when listening through a stethoscope. Numerous painless and mobile lymphadenopathies were observed in the cervical, axillary, and inguinal regions, the largest of which was less than 1 cm in diameter.

Laboratory examinations
Upon the patient’s first admission, the results of the blood tests were as follows (the values measured outside the reference range are given in bold, and the reference ranges are given in parentheses).

A complete blood count with differential was performed; white blood cells: 5.72 × 10³/μL (4.5–11), neutrophils: 3.84 × 10³/μL (2-7.8), lymphocytes: 1.37 × 10³/μL (1-4), monocytes: 0 (0-1), eosinophils: 0 (0-1), basophils: 0.042 × 10³/μL (0-0.2), hemoglobin: 9.9 gr/dL (12-16), hematocrit: 60.51% (35-46), and platelet count: 209 × 10³/μL (150-400).

All routine biochemical parameters measured in the venous blood were within normal limits, with the exception of the albumin level [2.78 g/L (3.5-5)], the total calcium level [7.5 mg/dL (8.4-10.2)], the potassium level [2.5 mmol/L (3.5-5.2)] and the phosphorus level [1.9 mg/dL (2.3-4.7)]. The C-reactive protein level was 28 mg/L (0-5), and the erythrocyte sedimentation rate (ESR) was 54 mm/hr (0-15). The fecal calprotectin level was > 1800 μg/g stool (< 50).

The pituitary and sex hormone levels were low in the luteal period of the cycle LH: 0.3 mIU/mL (5-20), FSH: 1.72 mIU/mL (3-20), Estradiol: 0.7 ng/mL (3-20). Other hormone levels: ACTH: 0.8 μg/dL (4-22), free T3: 1.2 pg/mL (1.71-3.71), free T4: 0.63 ng/dL (0.7-1.48), TSH: 0.273 mIU/mL (0.4-4.8).

Immunological examinations
The serum levels of all major immunoglobin isotypes were low during outpatient clinic admission. IgG: 4.15 g/L (6.52-16.31), IgA: 0.29 g/L (0.65-4.21), IgM: 0.23 g/L (0.33-2.93), and total IgE: < 1 IU/mL (< 87). The serum levels of the IgG subgroups were below the normal limits: IgG1: 3.05 g/L (4.05-10.11), IgG2: 1.73 g/L (1.69-7.86), IgG3: 0.62 g/L (0.11-0.85) and IgG4: 0.17 g/L (0.03-2.81). After retrospectively examining the laboratory results of the patient, it was found that the levels of the major serum immunoglobulins 4 mo prior were similar to the most recent measurements. The patient’s blood group was Rh + A, and the anti-B antibody titer was positive (+ + + +). The anti-hepatitis B antibody level was 511.3 U/L (< 10 U/L). The percentages of CD4+ T cells 18.2% (24.2-54.4), CD19+ B cells 3.3% (6.5-20.6), and the CD4/CD8 ratio 0.25% (0.7-3.6) were lower than the normal limits, while the percentages of CD3+ T cells 71.8% (51.3-83.5) and CD3-CD16-CD56+ NK cells 21.9% (3.7-28.5) were found within reference ranges. The percentage of CD8+ T cells 55.2% (12.8-40.2) was higher than the reference limits.

All auto-antibodies (anti-dsDNA, anti-histon, anti-RNP, anti-Sm, anti-SSA, anti SSB, anti Scl-70, anti-PM/Scl, anti-Jo1, anti-CEP-N, anti-PCNA, anti-nucleozen, anti-Rib-P-protein, anti-DPS70, anti-tissue transglutaminase, anti-endomysial, anti-gliadin) investigated using indirect immunofluorescence or immunoblot methods were negative. It should be kept in mind that in case of deficiencies of IgG and/or IgA, the autoantibodies can be observed as negative.
**Microbiological examinations**
In the sputum culture, *Pseudomonas Aeruginosa* growth was observed, and antibiotic treatment as oral levofloxacin 500 mg daily dose was administered to clear the infection. No bacteria, viruses, parasites, or parasitic eggs were detected in the stool tests.

**Imaging examinations**
Splenomegaly and enlargement of the para-aortic lymph nodes were detected using whole abdominopelvic ultrasonography and computed tomography. Peribronchiolar reticular and ground-glass infiltrations consistent with acute bronchiolitis were observed in the lower lobe of the right lung and the basal segments of the right middle lobe using high-resolution chest computed tomography.

No pathological observations were made from the radiological images of the pituitary and adrenal glands.

**Endoscopic examinations**
Upper and lower gastrointestinal tract endoscopies were performed due to the persistent diarrhea and treatment-resistant hypokalemia (Figure 1). An endoscopic examination revealed erosive gastritis, nodular duodenitis, and pancolitis.

**Histopathological examinations**
Histopathological examination of the duodenal biopsy specimen revealed features of active chronic duodenitis, characterized by villous blunting and expansion of the lamina propria due to mononuclear inflammation. In addition, an increase in the number of intraepithelial lymphocytes was observed. A colon biopsy revealed significant nodular lymphoid hyperplasia and a Graft-versus-Host Disease-like pattern with increased crypt epithelial apoptosis throughout the mucosa (Figure 2). These histopathological features indicated immune-mediated enteropathy.

**Genetic and flow cytometric analyses**
Targeted sequencing using next-generation sequencing technology was used for molecular diagnosis. A custom panel including STAT1, STAT3, STAT5B, CTLA4, LRBA, IL2RA, and FOXP3 was used for analysis. Although heterozygous polymorphisms (A2692T and S2797L) were identified in exons 54 and 56 of LRBA, a heterozygous polymorphism (T17A) was found in exon 1 of CTLA4. Pathological results were analyzed using flow cytometry at the expression level. Accordingly, the level of CTLA4 expression in the patient's PHA-stimulated CD3+ T cells was lower than that in healthy control (3.2 vs 16.6).

**FINAL DIAGNOSIS**
Considering the 2014 ESID criteria, the patient was diagnosed with CVID.

**TREATMENT**
Intravenous immunoglobulin (IVIG) treatment was initiated at a dose of 600 mg/kg every three weeks. Peroral and rectal therapeutic agents (i.e., methylprednisolone and mesalamine) were administered to treat the immune mediated bowel disease. Both intravenous and peroral potassium were used to treat life-threatening hypokalemia. After the genetic results were obtained, abatacept (CTLA-4-Ig fusion protein) treatment was started subcutaneously at a dose of 125 mg every two weeks. After a clinical response was observed in the third month of treatment, abatacept treatment was continued at the same dose once per month. At present, the patient is still being followed-up asymptotically with abatacept and IVIG treatment.

**OUTCOME AND FOLLOW-UP**
Three months after initiating the abatacept treatment, the patient exhibited decreased stool frequency and an increase in appetite. In the sixth month of treatment, her endoscopic and histopathological findings had regressed, and she had gained 11 kg.

**DISCUSSION**
In our case, the CTLA4 (T17A) and LRBA (A2692T, S2797L) variants were defined as benign in the ClinVar database. The A/G polymorphism at position 49 (codon 17) in exon 1 of CTLA4 results in a Thr17-to-Ala (T17A) substitution. The +49 A/G polymorphism has been extensively studied in autoimmune diseases. In two consecutive meta-analyses, the +49 A/G polymorphism was found to be associated with susceptibility to systemic lupus erythematosus. In addition, there are two reports that have suggested a relationship between the A allele of CTLA-4 +49 A/G and
susceptibility to celiac disease[9,10]. In one of these studies, this polymorphism was found to predispose patients to celiac disease, independent of HLA[9]. Another autoimmune disease that was found to be associated with the CTLA4 +49 A/G polymorphism is rheumatoid arthritis[11].

Abatacept, which is a CTLA4-Ig fusion protein, is a biologic agent that has been approved by the Food and Drug Administration for the treatment of rheumatoid arthritis[4]. Accordingly, we initiated abatacept treatment after genetic analyses were performed. Dramatic regression was observed in the clinical and laboratory findings shortly after abatacept treatment, with a 25% increase in weight within six months. Previous studies have also reported the successful use of this biological agent in LRBA deficiency and CTLA-4 haploinsufficiency[1,4].

Collen et al[4] reported two patients with CTLA-4 deficiency who were successfully treated with abatacept. Both patients were diagnosed with celiac disease prior to genetic diagnosis. Heterozygous mutations, c.457+2T>C and c71_72del (in exon 1), in the CTLA4 gene of the patients were identified using DNA sequencing. Despite following a gluten-free diet and undergoing various immunosuppressive treatments, the clinical course of these patients was severe. However, after abatacept treatment, the clinical findings of the patients were controlled.

As for the LRBA deficiency, Boz et al[12] reported a boy with early-onset refractory autoimmune gastritis with a biallelic mutation (c.C6415T p.R2139X in exon 42 and c.C7315T p.R2439X in exon 49) in the LRBA gene (chr 4; NM_006726; NP_006717) with whom long-term clinical remission had been achieved after abatacept treatment. In another report, Maggiore et al[13] presented a case of LRBA deficiency due to a homozygous mutation (c.1963C>T) in LRBA and unusual late-onset enteropathy. This patient had an atypical onset of LRBA deficiency with persistent fever, giant cervical lymphadenopathy, hepatosplenomegaly, and hypertransaminemia. Despite the use of high-dose intravenous immunoglobulins and various immunosuppressive drugs, treatment was unsuccessful. When abatacept treatment was initiated after genetic diagnosis, the clinical findings regressed and the effectiveness of the immunosuppressive drugs increased. In a multi-center study conducted by Kiykim et al[14], the long-term efficacy of abatacept was investigated in 22 patients.
with LRBA deficiency, and a superior clinical response was obtained in most patients when compared to previous therapies.

The LRBA polymorphisms detected in our patient were not associated with any particular disease in the genetic databases. Therefore, we concluded that the success achieved with abatacept treatment was not related to this variant. However, it has been reported that abatacept treatment provides improvement in patients with autoimmune diseases and immunodeficiencies due to LRBA deficiency[14].

CONCLUSION

The rapid recovery of our patient after abatacept treatment suggests that the polymorphic variant that we detected may be pathogenic. In adult patients with CVID and severe inflammatory complications of the gastrointestinal system, abatacept therapy should be considered as soon as CTLA4 variants are detected. However, further functional studies and intrafamilial segregation analyses are required to interpret the pathogenicity of these variants. These studies should be swiftly performed, as the results may help to better understand and define the pathophysiological and clinical consequences of the disease.

ACKNOWLEDGEMENTS

We thank the patient for her kindness and contribution to our study.

FOOTNOTES

Author contributions: All authors contributed to prepare the manuscript.

Informed consent statement: Patient perspective: The patient was pleased to receive a final diagnosis and treatment plan after many years without a solution to her medical problems, despite extensive diagnostic procedures. Written informed consent was obtained from the patient.

Conflict-of-interest statement: All the authors declare no conflicts of interest.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Turkey

ORCID number: Ugur Musabak 0000-0003-1511-7634; Tuba Erdoğan 0000-0002-3143-2442; Serdar Ceylaner 0000-0003-2786-1911; Emre Özbek 0000-0001-6345-8607; Nuretdin Suna 0000-0001-6234-7788; Binnaz Handan Özdemir 0000-0002-7528-3557.

S-Editor: Liu JH
L-Editor: A
P-Editor: Liu JH

REFERENCES


4 Collen LV, Salgado CA, Bao B, Janssen E, Weir D, Goldsmith J, Leichtner A, Sahbery Khavari N, Gernez Y, Snapper SB. Cytotoxic T
Musabak U et al. Abatacept treatment in a patient carrying a variant in CTLA4 gene


